Liquiritin apioside

Liquiritin apioside is an orally active inhibitor of TRPV1 receptor. Liquiritin apioside selectively inhibits laryngeal chemoreflex (LCR) and has no significant effect on mechanoreflex (LMR) . Liquiritin apioside inhibits LCR by inhibiting reactive oxygen species (ROS) and NADPH oxidase, weakening the interaction between ROS and TRPV1. Liquiritin apioside can be used in the research of respiratory-related diseases[1][2].

Product Specifications

CAS Number

[74639-14-8]

UNSPSC

12352005

Target

Others

Type

Natural Products

Related Pathways

Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/liquiritin-apioside.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@H]([C@H]1O[C@]2([H])OC[C@](O)(CO)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C3)=CC=C3[C@@H]4CC(C5=CC=C(O)C=C5O4)=O

Molecular Formula

C26H30O13

Molecular Weight

550.51

References & Citations

[1]Wei W, et al. Liquiritin apioside attenuates laryngeal chemoreflex but not mechanoreflex in rat pups. Am J Physiol Lung Cell Mol Physiol. 2020 Jan 1;318 (1) :L89-L97.|[2]Xia X, et al. Liquiritin apioside alleviates colonic inflammation and accompanying depression-like symptoms in colitis by gut metabolites and the balance of Th17/Treg. Phytomedicine. 2023 Nov;120:155039.